ANIP
ANI Pharmaceuticals, Inc.
ANIP's fundamentals are mixed, but it looks cheap: trading at 14x earnings, about a third of its usual 46x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ANIP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Unavailable | |
| Strong |
ANIP's profitability and balance sheet are currently healthy, and its revenue is stable. There isn't enough data to rate its cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ANIP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.5x | $71.06 | — |
| Current | 14x | $71.06 | — |
| Cheap | 21x | $103 | +45% |
| Fair | 46x | $228 | +221% |
| Expensive | 81x | $406 | +471% |
Historical ranges are pointers, not guarantees.
ANIP's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 7.5x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ANIP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for ANIP, but weaker profitability.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ANIP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.52 | +91% |
| Q3 2026 | $4.98 | +188% |
| Q2 2026 | $4.60 | +$5.27 |
| Q1 2026 | $3.91 | +$5.08 |
| Q4 2025 | $3.32 | +$4.36 |
| Q3 2025 | $1.73 | +$2.27 |
| Q2 2025 | -$0.67 | -157% |
| Q1 2025 | -$1.17 | -173% |
| Q4 2024 | -$1.04 | -222% |
ANIP has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ANIP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $148.3M | +13% |
| Q2 2024 | $138M | +18% |
| Q1 2024 | $137.4M | +29% |
| Q4 2023 | $131.7M | +40% |
| Q3 2023 | $131.8M | +57% |
| Q2 2023 | $116.5M | +58% |
| Q1 2023 | $106.8M | +66% |
| Q4 2022 | $94.2M | +55% |
HIMS has the stronger quarterly revenue trend. Revenue is up 13% for ANIP versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -14% | -27 points |
| Q2 2024 | 3.7% | -6.9 points |
| Q1 2024 | 15% | +5.5 points |
| Q4 2023 | 5.1% | +3.2 points |
| Q3 2023 | 14% | +20 points |
| Q2 2023 | 11% | +28 points |
| Q1 2023 | 9.3% | +39 points |
| Q4 2022 | 1.9% | +41 points |
ANIP's operating margin was −14% last quarter, down 27 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ANIP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $70.3M | +85% |
| Q2 2026 | $53.6M | -25% |
| Q1 2026 | $52.3M | +61% |
| Q4 2025 | $29.1M | +116% |
| Q3 2025 | $38M | +395% |
| Q2 2025 | $71.8M | +454% |
| Q1 2025 | $32.5M | +138% |
| Q4 2024 | $13.5M | -68% |
ANIP generated $205M in free cash flow over the past year, up 32% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ANIP on cash flow, with more consistent year-over-year improvement.
ANIP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -240K shares |
| 1 year | +2.8% | +582K shares |
| 3 years | +13% | +2.5M shares |
| 5 years | +79% | +9.6M shares |
| Available history | +80% | +9.6M shares |
ANIP has 22M diluted shares, up 2.8% from a year ago, despite $35M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.6M |
| Q2 2026 | $813,000 |
| Q1 2026 | $19.8M |
| Q4 2025 | $611,000 |
| Q3 2025 | $1M |
| Q2 2025 | $551,000 |
| Q1 2025 | $10M |
| Q4 2024 | $318,000 |
ANIP spent $35M buying back its own shares over the past year, up 192% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ANIP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ANIP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 2.5x | Moderate |
ANIP has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ANIP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 17.1 | Oversold |
ANIP's weekly RSI is 44 (neutral) and its Stochastic is 17 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ANIP PE vs Healthcare Sector
| Metric | ANIP | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 1 | 29 | 28 pts below |
ANIP is trading at 14x earnings, a 45% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ANIP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.9 | 1.2% below |
| 20 week MA | $75.0 | 5.3% below |
| 50 week MA | $77.5 | 8.3% below |
| 100 week MA | $74.7 | 4.9% below |
| 200 week MA | $65.2 | 8.9% above |
ANIP has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ANIP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.3 | $28.0 | -54% |
| 2021 | $28.0 | $50.9 | +82% |
| 2022 | $50.9 | $39.5 | -22% |
| 2023 | $39.5 | $55.1 | +40% |
| 2024 | $55.1 | $54.4 | -1.3% |
| 2025 | $54.4 | $82.4 | +51% |
| 2026 YTD | $82.4 | $71.1 | -14% |
ANIP has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.